STAT3 regulated ARF expression suppresses prostate cancer metastasis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Prostate cancer (PCa) is a leading cancer in men, with STAT3 signaling implicated in its progression.
• Current therapeutic strategies targeting the IL-6/STAT3 pathway have shown limited benefit in PCa patients.

Purpose of the Study:

• To investigate the role of STAT3 signaling in prostate cancer progression and metastasis.
• To elucidate the molecular mechanisms by which STAT3 influences tumor suppression in PCa.
• To identify potential prognostic markers for stratifying PCa patient risk.

Main Methods:

• Utilized a Pten-deficient mouse model of PCa to study the effects of Stat3 and IL-6 signaling inactivation.
• Performed genetic analysis to identify STAT3 and CDKN2A mutations in human PCa.
• Correlated STAT3 and p14(ARF) expression levels with disease recurrence and metastasis in patient cohorts.

Main Results:

• Inactivation of Stat3 or IL-6 signaling accelerated PCa progression and metastasis in a mouse model.
• Identified p19(ARF) as a direct Stat3 target, with Stat3 loss disrupting the ARF-Mdm2-p53 tumor suppressor axis and bypassing senescence.
• Found concurrent STAT3 and CDKN2A mutations in human PCa, with deletions frequently observed in metastases. Loss of STAT3 and p14(ARF) expression correlated with increased risk of recurrence and metastasis.

Conclusions:

• STAT3 functions as a tumor suppressor in PCa by regulating the ARF-Mdm2-p53 axis.
• STAT3 and ARF (encoded by CDKN2A) are potential prognostic markers for identifying high-risk PCa patients.
• Findings challenge the therapeutic utility of IL-6/STAT3 inhibition in PCa and suggest a context-dependent role for STAT3.